These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

614 related articles for article (PubMed ID: 19162488)

  • 1. Design, synthesis and biological evaluation of novel dual inhibitors of acetylcholinesterase and beta-secretase.
    Zhu Y; Xiao K; Ma L; Xiong B; Fu Y; Yu H; Wang W; Wang X; Hu D; Peng H; Li J; Gong Q; Chai Q; Tang X; Zhang H; Li J; Shen J
    Bioorg Med Chem; 2009 Feb; 17(4):1600-13. PubMed ID: 19162488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multi-target-directed coumarin derivatives: hAChE and BACE1 inhibitors as potential anti-Alzheimer compounds.
    Piazzi L; Cavalli A; Colizzi F; Belluti F; Bartolini M; Mancini F; Recanatini M; Andrisano V; Rampa A
    Bioorg Med Chem Lett; 2008 Jan; 18(1):423-6. PubMed ID: 17998161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pyrano[3,2-c]quinoline-6-chlorotacrine hybrids as a novel family of acetylcholinesterase- and beta-amyloid-directed anti-Alzheimer compounds.
    Camps P; Formosa X; Galdeano C; Muñoz-Torrero D; Ramírez L; Gómez E; Isambert N; Lavilla R; Badia A; Clos MV; Bartolini M; Mancini F; Andrisano V; Arce MP; Rodríguez-Franco MI; Huertas O; Dafni T; Luque FJ
    J Med Chem; 2009 Sep; 52(17):5365-79. PubMed ID: 19663388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Searching for the Multi-Target-Directed Ligands against Alzheimer's disease: discovery of quinoxaline-based hybrid compounds with AChE, H₃R and BACE 1 inhibitory activities.
    Huang W; Tang L; Shi Y; Huang S; Xu L; Sheng R; Wu P; Li J; Zhou N; Hu Y
    Bioorg Med Chem; 2011 Dec; 19(23):7158-67. PubMed ID: 22019465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis, in vitro assay, and molecular modeling of new piperidine derivatives having dual inhibitory potency against acetylcholinesterase and Abeta1-42 aggregation for Alzheimer's disease therapeutics.
    Kwon YE; Park JY; No KT; Shin JH; Lee SK; Eun JS; Yang JH; Shin TY; Kim DK; Chae BS; Leem JY; Kim KH
    Bioorg Med Chem; 2007 Oct; 15(20):6596-607. PubMed ID: 17681794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer's disease.
    Martone RL; Zhou H; Atchison K; Comery T; Xu JZ; Huang X; Gong X; Jin M; Kreft A; Harrison B; Mayer SC; Aschmies S; Gonzales C; Zaleska MM; Riddell DR; Wagner E; Lu P; Sun SC; Sonnenberg-Reines J; Oganesian A; Adkins K; Leach MW; Clarke DW; Huryn D; Abou-Gharbia M; Magolda R; Bard J; Frick G; Raje S; Forlow SB; Balliet C; Burczynski ME; Reinhart PH; Wan HI; Pangalos MN; Jacobsen JS
    J Pharmacol Exp Ther; 2009 Nov; 331(2):598-608. PubMed ID: 19671883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of acetylcholinesterase, beta-amyloid aggregation, and NMDA receptors in Alzheimer's disease: a promising direction for the multi-target-directed ligands gold rush.
    Rosini M; Simoni E; Bartolini M; Cavalli A; Ceccarini L; Pascu N; McClymont DW; Tarozzi A; Bolognesi ML; Minarini A; Tumiatti V; Andrisano V; Mellor IR; Melchiorre C
    J Med Chem; 2008 Aug; 51(15):4381-4. PubMed ID: 18605718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Secretase inhibitors and modulators for Alzheimer's disease treatment.
    Tomita T
    Expert Rev Neurother; 2009 May; 9(5):661-79. PubMed ID: 19402777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficient inhibition of the Alzheimer's disease beta-secretase by membrane targeting.
    Rajendran L; Schneider A; Schlechtingen G; Weidlich S; Ries J; Braxmeier T; Schwille P; Schulz JB; Schroeder C; Simons M; Jennings G; Knölker HJ; Simons K
    Science; 2008 Apr; 320(5875):520-3. PubMed ID: 18436784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis, and biological evaluation of dual binding site acetylcholinesterase inhibitors: new disease-modifying agents for Alzheimer's disease.
    Muñoz-Ruiz P; Rubio L; García-Palomero E; Dorronsoro I; del Monte-Millán M; Valenzuela R; Usán P; de Austria C; Bartolini M; Andrisano V; Bidon-Chanal A; Orozco M; Luque FJ; Medina M; Martínez A
    J Med Chem; 2005 Nov; 48(23):7223-33. PubMed ID: 16279781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design of potent inhibitors of human beta-secretase. Part 1.
    Freskos JN; Fobian YM; Benson TE; Bienkowski MJ; Brown DL; Emmons TL; Heintz R; Laborde A; McDonald JJ; Mischke BV; Molyneaux JM; Moon JB; Mullins PB; Bryan Prince D; Paddock DJ; Tomasselli AG; Winterrowd G
    Bioorg Med Chem Lett; 2007 Jan; 17(1):73-7. PubMed ID: 17046251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular-modeling based design, synthesis, and activity of substituted piperidines as gamma-secretase inhibitors.
    Gundersen E; Fan K; Haas K; Huryn D; Steven Jacobsen J; Kreft A; Martone R; Mayer S; Sonnenberg-Reines J; Sun SC; Zhou H
    Bioorg Med Chem Lett; 2005 Apr; 15(7):1891-4. PubMed ID: 15780628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis, and bioevaluation of benzamides: novel acetylcholinesterase inhibitors with multi-functions on butylcholinesterase, Aβ aggregation, and β-secretase.
    Peng DY; Sun Q; Zhu XL; Lin HY; Chen Q; Yu NX; Yang WC; Yang GF
    Bioorg Med Chem; 2012 Nov; 20(22):6739-50. PubMed ID: 23041347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Promising anti-Alzheimer's dimer bis(7)-tacrine reduces beta-amyloid generation by directly inhibiting BACE-1 activity.
    Fu H; Li W; Luo J; Lee NT; Li M; Tsim KW; Pang Y; Youdim MB; Han Y
    Biochem Biophys Res Commun; 2008 Feb; 366(3):631-6. PubMed ID: 18039469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Naphthyl and coumarinyl biarylpiperazine derivatives as highly potent human beta-secretase inhibitors. Design, synthesis, and enzymatic BACE-1 and cell assays.
    Garino C; Tomita T; Pietrancosta N; Laras Y; Rosas R; Herbette G; Maigret B; Quéléver G; Iwatsubo T; Kraus JL
    J Med Chem; 2006 Jul; 49(14):4275-85. PubMed ID: 16821787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design of potent inhibitors of human beta-secretase. Part 2.
    Freskos JN; Fobian YM; Benson TE; Moon JB; Bienkowski MJ; Brown DL; Emmons TL; Heintz R; Laborde A; McDonald JJ; Mischke BV; Molyneaux JM; Mullins PB; Bryan Prince D; Paddock DJ; Tomasselli AG; Winterrowd G
    Bioorg Med Chem Lett; 2007 Jan; 17(1):78-81. PubMed ID: 17049233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Therapy of Alzheimer disease].
    Kovács T
    Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Syntheses of coumarin-tacrine hybrids as dual-site acetylcholinesterase inhibitors and their activity against butylcholinesterase, Aβ aggregation, and β-secretase.
    Sun Q; Peng DY; Yang SG; Zhu XL; Yang WC; Yang GF
    Bioorg Med Chem; 2014 Sep; 22(17):4784-91. PubMed ID: 25088549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In silico discovery of beta-secretase inhibitors.
    Huang D; Lüthi U; Kolb P; Cecchini M; Barberis A; Caflisch A
    J Am Chem Soc; 2006 Apr; 128(16):5436-43. PubMed ID: 16620115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis and biological Evaluation of Dual acetyl cholinesterase and beta-secretase inhibitors in treatment for alzheimer's Disease.
    Deng Y; Jiang Y; Zhao X; Wang J
    Pak J Pharm Sci; 2019 Sep; 32(5):2091-2098. PubMed ID: 31813875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.